Impact of generic substitution of anticonvulsants on the treatment of epilepsy

CNS Drugs

Volumn 8, Issue 2, 1997, Pages 124-133

  Richens, Alan ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GENERIC DRUG; PHENYTOIN; PRIMIDONE; VALPROIC ACID;

BIOEQUIVALENCE; CONTROLLED RELEASE FORMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG FORMULATION; DRUG INDUSTRY; DRUG SOLUBILITY; EPILEPSY; FINANCE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE SYSTEM; HUMAN; LICENCE; MARKET; PATENT; PATIENT INFORMATION; PHARMACIST; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; REVIEW;

EID: 0030792462     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199708020-00004     Document Type: Review

References (68)

1. For and against generic prescribing. Drug Ther Bull 1987; 25: 24
2. Prescribing costs. Drug Ther Bull 1993; 31: 87
3. Snell ES. Generic substitution. BMJ 1983; 286: 1216-7
4. Hayward JL, Fentiman IS. Generic prescribing [letter]. BMJ 1986; 292: 762
5. Dill WA, Kazenko A, Wolf LM, et al. Studies on 5.5-diphenyl-hydantoin (Dilantin) in animals and man. J Pharmacol Exp Ther 1956; 118: 270-9
6. Martin CM, Rubin M, O'Malley WG, et al. Comparative physiological availability of brand and generic drugs in man: chloramphenicol. sulfisoxazole and dephenylhydantoin. Pharmacologist 1968; 10: 167
7. Glazko AJ. Diphenylhydantoin. In: Brodie BB, Haller WM, editors. Proceedings of the Conference on Bioavailability of Drugs. Basel: Karger, 1972: 163-77
8. Albert KS, Sakmar E, Hallmark MR, et al. Bioavailability of dephenylhydantoin. Clin Pharmacol Ther 1974; 16: 727-35
9. Lund L. Clinical significance of generic inequivalence of three different pharmaceutical preparations of phenytoin. Eur J Clin Pharmacol 1974; 7: 119-24
10. Alvan G, Bertler A, Eeg-Olofsson O, et al. Biological availability - a comparison of three phenytoin preparations. Lakartidningen 1975; 72: 2621-3
11. Appleton DB, Eadie MJ, Hooper WD, et al. Blood phenytoin concentrations produced by ingestion of three different phenytoin preparations. Med J Aust 1972; 59: 410-2
12. Sansom LH, O'Reilly WJ, Wiseman CW, et al. Plasma phenytoin levels produced by various phenytoin preparations. Med J Aust 1975; 2: 593-5
13. Manson JI, Beal SM, Magarey A, et al. Bioavailability of phenytoin from various pharmaceutical preparations in children. Med J Aust 1975; 2: 590-2
14. Partington MW, Reilly DM, Stewart JH, et al. Serum diphenyl-hydantoin levels following a change in drug brand. Can J Pharm Sci 1972; 9: 31-2
15. Rambeck B, Boenigk HE, Stenzel E. Bioavailability of three phenytoin preparations in healthy subjects and in epileptics. Eur J Clin Pharmacol 1977; 12: 285-90
16. Pentikainen PJ, Neuvonen PJ, Elfving SM. Bioavailability of four brands of phenytoin tablets. Eur J Clin Pharmacol 1975; 9: 213-8
17. Neuvonen PJ, Brady A, Lehtovaara R. Effect of increased bioavailability of phenytoin tablets on serum phenytoin concentration in epileptic outpatients. Br J Pharmacol 1979; 8: 37-41
18. Neuvonen PJ. Bioavailability of phenytoin. Clin Pharmacokinet 1979; 4: 91-103
19. Tammisto P, Kauko K, Viukari M. Bioavailability of phenytoin. Lancet 1976; 1: 254-5
20. Takahashi K, Honda J, Takahashi H, et al. Diphenylhydantoin blood levels in childhood epilepsy: a comparison of two preparations with different particle size. Brain Dev (Tokyo) 1979; 11: 278-84
21. Tsai J-J, Lau M-L, Yang Y-HK, et al. Comparison on bioequivalence of four phenytoin preparations in patients with multipledose treatment. J Clin Pharmacol 1992; 32: 272-6
22. Stewart MJ, Ballinger BR, Devlin EJ, et al. Bioavailability of phenytoin: a comparison of two preparations. Eur J Clin Pharmacol 1975; 9: 209-12
23. Chen S, Allen K, Oxley J, et al. Comparative bioavailability of phenytoin from generic formulations in the United Kingdom. Epilepsia 1982; 23: 149-52
24. Hirji MR, Measuria H, Kuhn S, et al. A comparative study of the bioavailability of five different phenytoin preparations. J Pharm Pharmacol 1985; 37: 570-2
25. Hodges S, Forsythe WI, Gillies D, et al. Bioavailability and dissolution of three phenytoin preparations for children. Dev Med Child Neurol 1986; 28: 708-12
26. Soryal I, Richens A. Bioavailability and dissolution of proprietary and generic formulations of phenytoin. J Neurol Neurosurg Psychiatry 1992; 55: 688-91
27. Mikati M, Bassett N, Schachter S. Double-blind randomised study comparing brand-name and generic phenytoin monotherapy. Epilepsia 1992; 33: 359-65
28. Tyrer JH, Eadie MJ, Sutherland JM, et al. Outbreak of anticonvulsant intoxication in an Australian city. BMJ 1970; 4: 271-3
29. Bochner R, Hooper WD, Tyrer JH, et al. Factors involved in an outbreak of phenytoin intoxication. J Neurol Sci 1972; 16: 481-7
30. Richens A, Dunlop A. Serum phenytoin levels in management of epilepsy. Lancet 1975; 2: 247-8
31. Richens A. Clinical pharmacology of phenytoin. Clin Pharmacokinet 1979; 4: 153-69
32. British national formulary, London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 1996; No. 31: 206
33. Nuwer MR, Browne TR, Dodson FE, et al. Generic substitutions for antiepileptic drugs. Neurology 1990; 40: 1647-51
34. Neuvonen PJ. Bioavailability and central side effects of different carbamazepine tablets, Int J Clin Pharmacol Ther Toxicol 1985; 23: 226-32
35. Faigle JW, Feldman KF. Pharmacokinetic data of carbamazepine and its major metabolites in man. In: Schneider H, Janz D, Gardner-Thorpe C, et al., editors. Clinical pharmacology of antiepileptic drugs. Berlin: Springer-Verlag, 1975: 166-80
36. Levy RH, Pitlick WH, Troupin AS, et al. Pharmacokinetics of carbamazepine in normal man. Clin Pharmacol Ther 1975; 17: 657-68
37. Kauko K, Tammisto P. Comparison of two generically equivalent carbamazepine preparations. Ann Clin Res 1974; 6 Suppl. 11: 21-5
38. Pynnonen S, Mantyla R, Iisalo E. Bioavailability of four different pharmaceutical preparations of carbamazepine. Acta Pharmacol Toxicol 1978; 43: 306-10
39. Anttila M, Kahela P, Panelius M, et al. Comparative bioavailability of two commercial preparations of carbamazepine tablets, Eur J Clin Pharmacol 1979; 15: 421-5
40. Morselli PL, Monaco F, Gerna M, et al. Bioavailability of two carbamazepine preparations during chronic administration of epileptic patients. Epilepsia 1975; 16: 759-64
41. Glende M, Huller H, Mai I, et al. Comparative bioavailability of two carbamazepine tablets. Int J Clin Pharmacol Ther Toxicol 1983; 21: 631-3
42. Jumao-as A, Bella I, Craig B, et al. Comparison of steady state blood levels of two carbamazepine formulations. Epilepsia 1989; 30: 67-70
43. Hartley R, Aleksandrowicz J, Ng PC, et al. Breakthrough seizures with generic carbamazepine: a consequence of poorer bioavailability? Br J Clin Pharmacol 1990; 44: 270-3
44. Hartley R, Aleksandrowicz J, Bowmer CJ, et al. Dissolution and relative bioavailability of two carbamazepine preparations for children with epilepsy. J Pharm Pharmacol 1991; 43: 117-9
45. Oles KS, Penry JK, Smith LD, et al. Therapeutic bioequivalency study of brand name versus generic carbamazepine. Neurology 1992; 42: 1147-53
46. Gilman JT, Alvarez LA, Duehowny M. Carbamazepine toxicity resulting from generic substitution. Neurology 1993; 43: 2696-7
47. Sachdeo R, Belendiuk G. Generic versus branded carbamazepine [letter]. Lancet 1987; 1: 1432
48. Koch G, Allen JP. Untoward effects of generic carhamazepine therapy [letler]. Arch Neurol 1987; 44: 578
49. Meyer MC, Straughn AB, Jarvi EJ, et al. The bioequivalence of carbamazepine tablets with a history of clinical failures. Pharm Res 1992; 9: 1612-6
50. Meyer MC, Straughn AB. Biopharmaceutical factors in seizure control and drug toxicity. Am J Hosp Pharm 1993; 50 Suppl.: S17-22
51. Wolf P, May T, Tiska G, et al. Steady state concentrations and diurnal fluctuations of carbamazepine in patients after slow release formulations. Drug Res 1992; 42: 284-8
52. Reunanen M, Heinonen EH, Nyman L, et al. Comparative bioavailability of carbamazepine from two slow-release preparations. Epilepsy Res 1992; 11: 61-6
53. Bialer M. Pharmacokinetic evaluation of sustained release formulations of antiepileptic drugs. Clin Pharmacokinet 1992; 22: 11-21
54. Patsalos PN. A comparative pharmacokinetic study of conventional and chewable carbamazepine in epileptic patients. Br J Clin Pharmacol 1990; 29: 574-7
55. Cornaggia C, Gianetti S, Battino D, et al. Comparative pharmacokinetic study of chewable and conventional carbamazepine in children. Epilepsia 1993; 34: 158-60
56. Perucca E, Gatti G, Frigo GM, et al. Pharmacokinetics of valproic acid after oral and intravenous administration. Br J Clin Pharmacol 1978; 5: 313-8
57. Klotz U, Antonin KH. Pharmacokinetics and bioavailability of sodium valproate. Clin Pharmacol Ther 1977; 21: 736-43
58. Macdonald JT. Breakthrough seizure following substitution of Depakene capsules (Abbott) with a generic product. Neurology 1987; 37: 1885
59. Trimble MR. Generic prescribing. Hum Psychopharmacol 1987; 2: 1-2
60. Bielmann P, Levac T, Langlois Y, et al. Bioavailability of primidone in epileptic patients. Int J Clin Pharmacol 1974; 9: 132-7
61. Wyllie E, Pippenger CE, Rothner AD. Increased seizure frequency with generic primidone. JAMA 1987; 258: 1216-7
62. Cloyd JC, Leppik IE. Primidone: absorption, distribution, excretion. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 459-66
63. Cramer JA, Mattson RH. Compliance with antiepileptic drug therapy. In. Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press. 1995: 149-59
64. Leppik IE, Cloyd JC, Sawchuk RJ, et al. Compliance and variability of plasma phenytoin levels in epileptic patients. Ther Drug Monit 1979; 1: 475-83
65. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261: 3273-7
66. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: generic substitution for antiepileptic medication. Neurology 1990; 40: 1641-3
67. FDA policy on generic anticonvulsants. Scrip 1989; 1469: 28
68. Food and Drug Administration. FDA findings on generic drugs. PDA Drug Bull 1990; 20: 4-5